Generic Name: cabotegravir
Drug Class: Integrase Inhibitors
Company: ViiV Healthcare
Approval Status: Approved
Generic Version Available: No
Drug Indication
Cabotegravir is a medication for HIV treatment. Vocabria pills are approved for use with Edurant (rilpivirine) as a short-term treatment regimen. Vocabria has not yet been reviewed for inclusion in the DHHS list of recommended medications for HIV treatment or prevention.
Cabenuva is a long-acting treatment regimen that consists of extended-release cabotegravir and rilpivirine injections. Long-acting injectable cabotegravir is also approved for pre-exposure prophylaxis (PrEP) as Apretude.
General Info
Vocabria is an integrase inhibitor antiretroviral medication. It is used with Edurant (rilpivirine) for short-term HIV treatment. The pills are used as a lead-in regimen for people who want to switch to Cabenuva injections and may be substitute if someone has to miss a planned injection appointment.
Dosage
Dosing Info:
Vocabria pills are taken once daily, in combination with once-daily Edurant pills, as a oral lead-in regimen for a month before switching to Cabenuva injections.
Side Effects
The most commonly reported side effects are headache, nausea, abnormal dreams, anxiety and insomnia.
Drug Interactions
For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Vocabria or may require dose adjustments, consult the Vocabria package insert.
Other Info
https://www.poz.com/article/viiv-applies-approval-first-longacting-injectable-hiv-regimen
For More Info: https://viivhealthcare.com/en-gb/our-medicines/vocabria/
Patient Assistance Program Info: https://www.viivconnect.com/patient-assistance-program/
Last Reviewed: January 24, 2021
